RyanChristopherLynchMD

Oncology • Seattle, WA

Hematologic Oncology

Instructor, Internal Medicine, Washington University in St. Louis School of Medicine

Join to view full profile

Dr. Lynch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lynch's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-288-7222

Fax+1 314-362-9878

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2017
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2010 - 2013
Boston University School of MedicineClass of 2010

Certifications & Licensure

CA State Medical License 2014 - Present
AK State Medical License 2022 - 2026
ID State Medical License 2022 - 2025
WA State Medical License 2017 - 2025
NY State Medical License 2012 - 2018
MO State Medical License 2012 - 2015

Publications & Presentations

PubMed

1 citations
Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma.
Ryan C Lynch, Michael Sargent Binkley
Seminars in Radiation Oncology. 2025-01-01
Has PD-1 blockade changed the standard of care for cHL?
Thomas M Kuczmarski, Ryan C Lynch
Hematology. American Society of Hematology. Education Program. 2024-12-06
A phase 2 study of frontline pembrolizumab in follicular lymphoma.
Carrie Ho, Songli Zhu, Ted Gooley, Taranjit S Gujral, Ryan C Lynch
Ejhaem. 2024-12-01

Abstracts/Posters

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business HighlightsAugust 9th, 2021
Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA) Clinicians to Be Featured at the 2021 ASCO Annual MeetingJune 3rd, 2021
Sunburn — the Morning Read of What’s Hot in Florida Politics — 3.16.21March 16th, 2021
Join now to see all